Stock BGNE BEIGENE, LTD.
Add to a list
To use this feature you must be a member
Log inSign up

News BeiGene, Ltd.

Equities

BGNE

US07725L1026

Delayed Nasdaq
Other stock markets
 03:46:05 2024-04-25 pm EDT 		5-day change 1st Jan Change
148.2 USD +2.87% Intraday chart for BeiGene, Ltd. +11.95% -18.09%
Apr. 23 Sector Update: Health Care Stocks Rise in Afternoon Trading MT
Apr. 23 BeiGene Says Tislelizumab Gets European Commission's Approval to Treat Non-Small Cell Lung Cancer; Shares Rise MT

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Global Oncology Innovator BeiGene Highlights New Data across Hematology and Solid Tumor Portfolio at 2024 ASCO Annual Meeting
BU
Sector Update: Health Care Stocks Rise in Afternoon Trading
MT
BeiGene Says Tislelizumab Gets European Commission's Approval to Treat Non-Small Cell Lung Cancer; Shares Rise
MT
BeiGene Shares Rise 7% After European Approval of Tislelizumab Cancer Treatment
DJ
Technology Stocks Lead Asian Equities Traded in the US as American Depositary Receipts Higher in Tuesday Trading
MT
BeiGene Says Tislelizumab Gets European Commission's Approval to Treat Non-Small Cell Lung Cancer
MT
BeiGene Receives European Commission Approval for Tislelizumab as Treatment for Non-Small Cell Lung Cancer
BU
BeiGene, Ltd. Receives European Commission Approval for Tislelizumab as Treatment for Non-Small Cell Lung Cancer
CI
BeiGene to Award Shares Worth $15 Million to 11 Directors
MT
Western Drugmakers Seeking Alternative Suppliers as US Looks to Restrict Chinese Biotech
MT
Western Drugmakers Seeking Alternative Suppliers as US Looks to Restrict Chinese Biotech
MT
BeiGene Opens New Factory in Guangzhou for Antibody-Drug Conjugates
MT
Beigene Shrinks Loss by 56% in 2023
MT
Bernstein Adjusts BeiGene's Price Target to $161 From $196, Maintains Market Perform Rating
MT
Tech Stocks Lead Asian Equities Traded in the US as American Depositary Receipts Slightly Lower in Friday Trading
MT
BeiGene, Ltd. Announces Executive Changes
CI
BeiGene Receives FDA Approval for TEVIMBRA for the Treatment of Advanced or Metastatic Esophageal Squamous Cell Carcinoma after Prior Chemotherapy
AQ
Beigene's Esophageal Cancer Drug Gets US FDA Nod
MT
Beigene Insider Sold Shares Worth $8,368,017, According to a Recent SEC Filing
MT
BeiGene Says FDA Approves Tevimbra to Treat Some Esophageal Cancer Patients
DJ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. BGNE Stock
  4. News BeiGene, Ltd.